CommercialPrior AuthHigh impact
Lung Transplantation (CPB 0598, reviewed 2025-12-02)
Aetna·Transplant Surgery, Pulmonology, Cardiothoracic Surgery +1 more·Medical Policy
Effective date
Dec 2, 2025
We identified it
Aug 19, 2026
Summary
Aetna has issued a comprehensive medical policy (CPB 0598) establishing medical necessity criteria for lung transplantation across multiple qualifying conditions (cystic fibrosis, emphysema, pulmonary fibrosis, primary pulmonary hypertension, Eisenmenger's complex, sarcoidosis, and others). The policy defines general selection criteria, disease-specific clinical criteria, and absolute contraindications that must be met before lung transplant authorization. Billing teams must implement prior authorization workflows requiring documentation of these specific clinical criteria before submitting transplant-related claims.
Action Required
By December 2, 2025: (1) Billing team must establish prior authorization workflow requiring transplant centers to submit clinical documentation proving patient meets BOTH general selection criteria AND applicable disease-specific criteria before any lung transplant procedures are billed. (2) Create pre-authorization checklist in billing system for each qualifying condition (CF, emphysema, pulmonary fibrosis, pulmonary hypertension, Eisenmenger's, sarcoidosis, LAM, bronchopulmonary dysplasia, etc.). (3) Verify all required clinical documentation is present before claim submission: for CF patients—at least 2 deterioration signs; for emphysema—COPD exacerbation hospitalizations with hypercapnia AND BODE index ≥7 or cor pulmonale; for pulmonary fibrosis—DLCO <60%, cor pulmonale, or TLC <70%; for pulmonary hypertension—NYHA III status failing vasodilators or mean PAP >25 mmHg at rest. (4) Deny and return any claims lacking required clinical evidence without submitting to Aetna. (5) Providers and transplant centers must document contraindication screening (no active infection, adequate cardiac/liver/kidney function, ejection fraction >40%, creatinine clearance >50, CD4 >200 if HIV+, no malignancy, no uncontrolled psychiatric disease). (6) Implement monthly audit of lung transplant authorizations to ensure compliance. Failure to obtain documented authorization will result in claim denials and potential contractual penalties.